Greenwich LifeSciences (GLSI) Competitors $11.44 +0.21 (+1.87%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$11.46 +0.03 (+0.22%) As of 10/8/2025 05:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLSI vs. CMPS, CRVS, ZVRA, ESPR, ORGO, CMPX, BCYC, PRTA, RGNX, and SLDBShould you be buying Greenwich LifeSciences stock or one of its competitors? The main competitors of Greenwich LifeSciences include COMPASS Pathways (CMPS), Corvus Pharmaceuticals (CRVS), Zevra Therapeutics (ZVRA), Esperion Therapeutics (ESPR), Organogenesis (ORGO), Compass Therapeutics (CMPX), Bicycle Therapeutics (BCYC), Prothena (PRTA), REGENXBIO (RGNX), and Solid Biosciences (SLDB). These companies are all part of the "pharmaceutical products" industry. Greenwich LifeSciences vs. Its Competitors COMPASS Pathways Corvus Pharmaceuticals Zevra Therapeutics Esperion Therapeutics Organogenesis Compass Therapeutics Bicycle Therapeutics Prothena REGENXBIO Solid Biosciences Greenwich LifeSciences (NASDAQ:GLSI) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk. Does the media prefer GLSI or CMPS? In the previous week, Greenwich LifeSciences had 1 more articles in the media than COMPASS Pathways. MarketBeat recorded 3 mentions for Greenwich LifeSciences and 2 mentions for COMPASS Pathways. COMPASS Pathways' average media sentiment score of 0.84 beat Greenwich LifeSciences' score of -0.59 indicating that COMPASS Pathways is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Greenwich LifeSciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative COMPASS Pathways 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, GLSI or CMPS? Greenwich LifeSciences is trading at a lower price-to-earnings ratio than COMPASS Pathways, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGreenwich LifeSciencesN/AN/A-$15.79M-$1.36-8.41COMPASS PathwaysN/AN/A-$155.12M-$1.84-3.59 Do analysts rate GLSI or CMPS? Greenwich LifeSciences presently has a consensus target price of $42.00, suggesting a potential upside of 267.13%. COMPASS Pathways has a consensus target price of $16.29, suggesting a potential upside of 146.75%. Given Greenwich LifeSciences' higher possible upside, analysts plainly believe Greenwich LifeSciences is more favorable than COMPASS Pathways.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Greenwich LifeSciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33COMPASS Pathways 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 Do insiders and institutionals have more ownership in GLSI or CMPS? 4.2% of Greenwich LifeSciences shares are owned by institutional investors. Comparatively, 46.2% of COMPASS Pathways shares are owned by institutional investors. 51.7% of Greenwich LifeSciences shares are owned by insiders. Comparatively, 3.9% of COMPASS Pathways shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk and volatility, GLSI or CMPS? Greenwich LifeSciences has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 2.21, meaning that its share price is 121% more volatile than the S&P 500. Is GLSI or CMPS more profitable? COMPASS Pathways' return on equity of -87.89% beat Greenwich LifeSciences' return on equity.Company Net Margins Return on Equity Return on Assets Greenwich LifeSciencesN/A -700.90% -455.64% COMPASS Pathways N/A -87.89%-57.77% SummaryCOMPASS Pathways beats Greenwich LifeSciences on 8 of the 13 factors compared between the two stocks. Get Greenwich LifeSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GLSI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLSI vs. The Competition Export to ExcelMetricGreenwich LifeSciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$153.07M$3.35B$6.10B$10.55BDividend YieldN/A2.28%5.69%4.75%P/E Ratio-8.4121.5785.4727.60Price / SalesN/A426.57601.78232.87Price / CashN/A47.1237.9261.55Price / Book60.2110.1413.136.76Net Income-$15.79M-$52.31M$3.30B$275.88M7 Day Performance7.42%5.14%4.29%2.81%1 Month Performance4.00%14.68%9.45%9.24%1 Year Performance-11.66%30.98%86.64%35.42% Greenwich LifeSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLSIGreenwich LifeSciences1.1022 of 5 stars$11.44+1.9%$42.00+267.1%-15.6%$153.07MN/A-8.413CMPSCOMPASS Pathways3.164 of 5 stars$5.87+1.2%$16.29+177.4%+9.5%$556.46MN/A-3.19120Analyst ForecastCRVSCorvus Pharmaceuticals1.8943 of 5 stars$7.28-1.5%$13.00+78.6%+17.8%$550.66MN/A-7.2130News CoverageAnalyst ForecastZVRAZevra Therapeutics2.6642 of 5 stars$9.54-2.4%$24.00+151.6%+27.1%$548.44M$23.61M-45.4320ESPREsperion Therapeutics3.8129 of 5 stars$2.64-0.4%$7.00+165.2%+24.2%$534.30M$332.31M-5.39200Analyst ForecastGap DownORGOOrganogenesis3.72 of 5 stars$4.26+3.9%$7.33+72.1%+38.1%$520.12M$482.04M-30.43950Analyst ForecastCMPXCompass Therapeutics2.5926 of 5 stars$3.82+2.1%$13.88+263.2%+125.4%$517.18MN/A-8.4920Positive NewsAnalyst ForecastBCYCBicycle Therapeutics3.7142 of 5 stars$7.61+2.8%$22.22+192.0%-64.9%$512.87M$35.28M-2.17240Gap UpPRTAProthena3.0473 of 5 stars$9.76+3.7%$19.75+102.4%-38.0%$506.54M$10.34M-1.73130Analyst ForecastRGNXREGENXBIO4.4898 of 5 stars$9.85+2.1%$28.38+188.1%+27.8%$487.46M$83.33M-2.86370News CoverageAnalyst ForecastSLDBSolid Biosciences2.7824 of 5 stars$5.97-2.9%$15.00+151.3%-10.9%$478.89M$8.09M-2.13100Analyst Forecast Related Companies and Tools Related Companies CMPS Competitors CRVS Competitors ZVRA Competitors ESPR Competitors ORGO Competitors CMPX Competitors BCYC Competitors PRTA Competitors RGNX Competitors SLDB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLSI) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Greenwich LifeSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Greenwich LifeSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
